Customize
Quick Links
Past Events

Accreditation/
Credit Designation

Physicians' Education Resource®, LLC is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
 
Physicians' Education Resource®, LLC designates this live activity for a maximum of 6.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Commercial Supporters

This activity is supported in part by educational grants from Abbott, Bayer HealthCare Pharmaceuticals Inc., Dendreon, Ferring Pharmaceuticals, Inc. and sanofi-aventis U.S.
About
Accreditation
Privacy Policy
Terms & Conditions
Executive Board
Journal
Faculty Portal
Contact
Facebook
Twitter
LinkedIn
Google +
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 800-210-2873

Copyright © 2017
Physicians’ Education Resource ®, LLC.
All rights reserved.

5th Annual Interdisciplinary Prostate Cancer Congress™

5th Annual Interdisciplinary Prostate Cancer Congress™


Intercontinental New York Barclay
New York, NY
March 31, 2012

Conference Overview
Prostate cancer is one of the most common cancers in men, affecting 1 out of every 6 men in the United States. Each year, it is diagnosed in 234,460 men and approximately 27,000 die as a result. Fortunately, continued progress has been made in the treatment of prostate cancer over the past 5 years, and improvements in both strategies and available therapeutic agents have increased survival rates for patients with prostate cancer.

Physicians’ Education Resource®, LLC (PER®) will host its Fifth Annual Interdisciplinary Prostate Cancer Congress (IPCC) at the New York Marriott East Side in New York City. This full-day continuing medical education (CME) activity entitled Novel Perspectives – Evolving Therapies and Advances In Standard of Care will address the differences that currently exist between urologists’, medical oncologists’, and radiation oncologists’ approaches to treating prostate cancer.

World-renowned thought leaders have been brought together to foster consensus about the best management of prostate cancer from the vantage point of interdisciplinary care teams. Topics of vital interest that will be include: hormonal therapies; imaging and staging; surgical advances; radiation therapies; and emerging multimodal therapies. The IPCC will include interactive cases designed to highlight multidisciplinary approaches for the management of prostate cancer with the overall goal of improving patient outcomes.

Target Audience
Urologists, medical oncologists, and radiation oncologists who treat patients with prostate cancer.

Learning Objectives
After completing this activity, participants should be able to:
  • Recognize the advantages and disadvantages of screening and early detection in prostate cancer
  • Review the current standard of care for patients with early-stage, localized, androgen-dependent, and hormone refractory and/or castrate-resistant metastatic prostate cancer and apply them to clinical practice
  • Incorporate newly approved agents for maintaining bone health into therapeutic regimens for patients with prostate cancer
  • Compare the similarities and disparities among current practice guidelines for prostate cancer management and select the guidelines for use in clinical practice
  • Evaluate the efficacy and safety of emerging therapeutic strategies in prostate cancer and counsel patients on appropriate clinical trials  
  • Formulate an optimal interdisciplinary plan for the management of their patients with prostate cancer.






Become a Member

Forgot Password?
Filter By